Therapeutic antibody gene transfer: An active approach to passive immunity

Molecular Therapy

Volumn 10, Issue 3, 2004, Pages 411-416

  Bakker, Joost M ^a   Bleeker, Wim K ^a   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; AUTOANTIGEN; B7 ANTIGEN; BASILIXIMAB; CHIMERIC PROTEIN; CYTOKINE; DNA VACCINE; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INFLIXIMAB; MONOCLONAL ANTIBODY; NAKED DNA; NEUTRALIZING ANTIBODY; OKT 3; ORTHOCLONE; PALIVIZUMAB; PLASMID DNA; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BREAST CANCER; CANCER RECURRENCE; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG TARGETING; ELECTROPORATION; ENTERITIS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; GENE TRANSFER; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; IN VIVO STUDY; KIDNEY ALLOGRAFT REJECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPPORTUNISTIC INFECTION; PASSIVE IMMUNIZATION; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ANTIBODIES; AUTOIMMUNITY; COMMUNICABLE DISEASES; ELECTROPORATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNIZATION, PASSIVE;

EID: 4444260465     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.06.865     Document Type: Review

References (74)

1. M.J. Glennie van de Winkel J.G. Renaissance of cancer therapeutic antibodies Drug Discovery Today 8 2003 503-510
2. T. Gura Therapeutic antibodies: magic bullets hit the target Nature 417 2002 584-586
3. T. Shinkawa The absence of fucose but not the presence of galactose or bisecting N -acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J. Biol. Chem. 278 2003 3466-3473
4. R.L. Shields Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity J. Biol. Chem. 277 2002 26733-26740
5. R.L. Shields High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R J. Biol. Chem. 276 2001 6591-6604
6. L.C. Simmons Expression of full-length immunoglobulins in Escherichia coli : rapid and efficient production of aglycosylated antibodies J. Immunol. Methods 263 2002 133-147
7. S.R. Hamilton Production of complex human glycoproteins in yeast Science 301: 2003 1244-1246
8. J.A. St George Gene therapy progress and prospects: adenoviral vectors Gene Ther. 10 2003 1135-1141
9. D. Noel M. Pelegrin S. Kramer C. Jacquet N. Skander M. Piechaczyk High in vivo production of a model monoclonal antibody on adenoviral gene transfer Hum. Gene Ther. 13 2002 1483-1493
10. A.D. Lewis R. Chen D.C. Montefiori P.R. Johnson K.R. Clark Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer J. Virol. 76 2002 8769-8775
11. T. Gura Gene therapy and the germ line Mol. Ther. 6 2002 2-4
12. D. Ferber Gene therapy: safer and virus-free? Science 294 2001 1638-1642
13. E. Marshall Gene therapy: what to do when clear success comes with an unclear risk? Science 298 2002 510-511
14. Y. Yang F.A. Nunes K. Berencsi E.E. Furth E. Gonczol J.M. Wilson Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy Proc. Natl. Acad. Sci. USA 91 1994 4407-4411
15. K. Jooss N. Chirmule Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy Gene Ther. 10 2003 955-963
16. G.J. Prud'homme B.R. Lawson Y. Chang A.N. Theofilopoulos Immunotherapeutic gene transfer into muscle Trends Immunol. 22 2001 149-155
17. E. Raz Systemic immunological effects of cytokine genes injected into skeletal muscle Proc. Natl. Acad. Sci. USA 90 1993 4523-4527
18. X.Y. Song M. Gu W.W. Jin D.M. Klinman S.M. Wahl Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model J. Clin. Invest. 101 1998 2615-2621
19. Y. Chang G.J. Prud'homme Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity J. Gene Med. 1 1999 415-423
20. B.R. Lawson Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc J. Clin. Invest. 106 2000 207-215
21. G.J. Prud'homme Y. Chang Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein Gene Ther. 6 1999 771-777
22. C.A. Piccirillo Y. Chang G.J. Prud'homme TGF-beta1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice J. Immunol. 161 1998 3950-3956
23. C.A. Piccirillo G.J. Prud'homme Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors Hum. Gene Ther. 10 1999 1915-1922
24. F. Liu Y. Song D. Liu Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA Gene Ther. 6 1999 1258-1266
25. H. Herweijer J.A. Wolff Progress and prospects: naked DNA gene transfer and therapy Gene Ther. 10 2003 453-458
26. J. Jiang E. Yamato J. Miyazaki Intravenous delivery of naked plasmid DNA for in vivo cytokine expression Biochem. Biophys. Res. Commun. 289 2001 1088-1092
27. G. Zhang V. Budker P. Williams V. Subbotin J.A. Wolff Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates Hum. Gene Ther. 12 2001 427-438
28. I. Tranchant B. Thompson C. Nicolazzi N. Mignet D. Scherman Physicochemical optimisation of plasmid delivery by cationic lipids J. Gene Med. 6 Suppl. 1 2004 S24-S35
29. T. Niidome L. Huang Gene therapy progress and prospects: nonviral vectors Gene Ther. 9 2002 1647-1652
30. S. Somiari Theory and in vivo application of electroporative gene delivery Mol. Ther. 2 2000 178-187
31. M.J. Jaroszeski R. Gilbert C. Nicolau R. Heller In vivo gene delivery by electroporation Adv. Drug Delivery Rev. 35 1999 131-137
32. H. Aihara J. Miyazaki Gene transfer into muscle by electroporation in vivo Nat. Biotechnol. 16 1998 867-870
33. L.M. Mir High-efficiency gene transfer into skeletal muscle mediated by electric pulses Proc. Natl. Acad. Sci. USA 96 1999 4262-4267
34. G. Rizzuto Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation Proc. Natl. Acad. Sci. USA 96 1999 6417-6422
35. I. Mathiesen Electropermeabilization of skeletal muscle enhances gene transfer in vivo Gene Ther. 6 1999 508-514
36. R. Heller Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin Cancer 83 1998 148-157
37. A. Gothelf L.M. Mir J. Gehl Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation Cancer Treat. Rev. 29 2003 371-387
38. Z.F. Zhou Y. Peretz Y. Chang D.S. Miao X. Li G.J. Prud'homme Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination Cancer Gene Ther. 10 2003 491-499
39. J.M. Kim Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein Gene Ther. 10 2003 1216-1224
40. L. Grossin Direct gene transfer into rat articular cartilage by in vivo electroporation 17 2003 829-835
41. R. Heller In vivo gene electroinjection and expression in rat liver FEBS Lett. 389 1996 225-228
42. L. Zhang L. Li G.A. Hoffmann R.M. Hoffman Depth-targeted efficient gene delivery and expression in the skin by pulsed electric fields: an approach to gene therapy of skin aging and other diseases Biochem. Biophys. Res. Commun. 220 1996 633-636
43. S. Babiuk Electroporation improves the efficacy of DNA vaccines in large animals Vaccine 20 2002 3399-3408
44. J.P. Scheerlinck J. Karlis T.E. Tjelle P.J. Presidente I. Mathiesen S.E. Newton In vivo electroporation improves immune responses to DNA vaccination in sheep Vaccine 22 2004 1820-1825
45. L. Zhang G. Widera S. Bleecher D.A. Zaharoff B. Mossop D. Rabussay Accelerated immune response to DNA vaccines DNA Cell Biol. 22 2003 815-822
46. S. Tollefsen Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation Vaccine 20 2002 3370-3378
47. H. Potter L. Weir P. Leder Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation Proc. Natl. Acad. Sci. USA 81 1984 7161-7165
48. S.K. Foung S. Perkins Electric field-induced cell fusion and human monoclonal antibodies J. Immunol. Methods 116 1989 117-122
49. T.E. Tjelle Monoclonal antibodies produced by muscle after plasmid injection and electroporation Mol. Ther. 9 2004 328-336
50. N. Perez P. Bigey D. Scherman O. Danos M. Piechaczyk M. Pelegrin Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation Genet. Vaccines Ther. 2 2004 2
51. M.J. Glennie P.W. Johnson Clinical trials of antibody therapy Immunol. Today 21 2000 403-410
52. M.Q. Xia Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis Biochem. J. 293 Pt. 3 1993 633-640
53. J. Baselga J. Albanell Mechanism of action of anti-HER2 monoclonal antibodies Ann. Oncol. 12 Suppl. 1 2001 S35-S41
54. L.H. Calabrese Molecular differences in anticytokine therapies Clin. Exp. Rheumatol. 21 2003 241-248
55. L.S. Villadsen Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model J. Clin. Invest. 112 2003 1571-1580
56. M. Mandal L. Adam J. Mendelsohn R. Kumar Nuclear targeting of Bax during apoptosis in human colorectal cancer cells Oncogene 17 1998 999-1007
57. W.K. Bleeker Dual mode of action of a human anti-EGF receptor monoclonal antibody for cancer therapy J. Immunol. 2004 in press
58. J.M. Kovarik A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic -dynamic evaluations Transplantation 74 2002 966-971
59. C. Sgro Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review Toxicology 105 1995 23-29
60. B. Leyland-Jones Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J. Clin. Oncol. 21 2003 3965-3971
61. E.W. St. Clair The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum. 46 2002 1451-1459
62. H.L. Zaaijer C.M. Vandenbroucke-Grauls E. Franssen Optimum dosage regimen of palivizumab? Ther. Drug Monit. 24 2002 444-445
63. D.G. Maloney IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J. Clin. Oncol. 15 1997 3266-3274
64. E.C. Morris Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications Blood 102 2003 404-406
65. W.K. Bleeker J.L. Teeling C.E. Hack Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect Blood 98 2001 3136-3142
66. S. Sell J.L. Fahey Relationship between gamma-globulin metabolism and low serum gamma-globulin in germfree mice J. Immunol. 93 1964 81-87
67. T.A. Waldmann W. Strober Metabolism of immunoglobulins Prog. Allergy 13 1969 1-110
68. J. Albanell J. Codony A. Rovira B. Mellado P. Gascon Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 Adv. Exp. Med. Biol. 532 2003 253-268
69. P. Rutgeerts G. Van Assche S. Vermeire Optimizing anti-TNF treatment in inflammatory bowel disease Gastroenterology 126 2004 1593-1610
70. S. Kroesen A.F. Widmer A. Tyndall P. Hasler Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy Rheumatology (Oxford) 42 2003 617-621
71. C.A. Dinarello Anti-cytokine therapeutics and infections Vaccine 21 Suppl. 2 2003 S24-S34
72. J. Keane Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N. Engl. J. Med. 345 2001 1098-1104
73. P.W. Parren J.P. Moore D.R. Burton Q. Sattentau The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity AIDS 13 Suppl. A 1999 S137-S162
74. M.B. Zwick Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies J. Virol. 75 2001 12198-12208